GlobeNewswire
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
📈
AI Sentiment
Highly Positive
9/10
- Home
- PSTV
as of 12-04-2025 4:00pm EST
$0.66
+$0.06
+9.77%
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Chart Type:
Time Range:
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 61.1M | IPO Year: | N/A |
| Target Price: | $7.25 | AVG Volume (30 days): | 5.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.16 - $2.31 | Next Earning Date: | 10-30-2025 |
| Revenue: | $5,258,000 | Revenue Growth: | -8.16% |
| Revenue Growth (this year): | 28.21% | Revenue Growth (next year): | -2.71% |
AI-Powered PSTV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.87%
76.87%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of PLUS THERAPEUTICS Inc. (PSTV)
Sims Andrew John Hugh MacIntyre
Buy
Chief Financial Officer
PSTV Nov 4, 2025
Avg Cost/Share
$0.51
Shares
20,000
Total Value
$10,200.00
Owned After
68,138
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sims Andrew John Hugh MacIntyre | PSTV | Chief Financial Officer | Nov 4, 2025 | Buy | $0.51 | 20,000 | $10,200.00 | 68,138 |
Latest PLUS THERAPEUTICS Inc. News
PSTV Breaking Stock News: Dive into PSTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
📊
AI Sentiment
Positive
7/10
Compare PSTV vs Leading Stocks
See how PSTV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PSTV PLUS THERAPEUTICS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.